SA PRO
Free Account
Themes
Pfizer Inc.PFENYSE
Loading
OverviewIntelligenceChartsNews

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
20 analysts·High coverage
30%
Rating Distribution
Strong Buy
00%
Buy
630%
Hold
1470%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case
$24.00
-10%
Consensus
$27.36
+3%
Bull Case
$35.00
+32%
Price Range20 analysts
Low
Consensus
High
$24.00
$35.00
Current Target
Current Price
$26.61
Upside to Target
$0.75

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Feb 24, 2026RBC Capital
RBC Capital Starts Pfizer (PFE) at Underperform
Target:$25.00
-7.9%from $27.14
Feb 19, 2026Barclays
Pfizer initiated with an Underweight at Barclays
Target:$25.00
-6.9%from $26.86
Feb 12, 2026Daiwa
Pfizer downgraded to Neutral from Outperform at Daiwa
Target:$27.00
-2.6%from $27.73
Jan 27, 2026Cantor Fitzgerald
Pfizer price target raised to $27 from $24 at Cantor Fitzgerald
Target:$27.00
+4.3%from $25.88
Jan 6, 2026UBS
Pfizer assumed with a Neutral at UBS
Target:$25.00
-1.7%from $25.43
Dec 17, 2025Wolfe Research
Pfizer (PFE) PT Lowered to $24 at Wolfe Research
Target:$24.00
-6.0%from $25.53
Dec 12, 2025Morgan Stanley
Pfizer price target lowered to $28 from $32 at Morgan Stanley
Target:$28.00
+8.1%from $25.89
Dec 10, 2025HSBC
Pfizer price target raised to $29 from $28 at HSBC
Target:$29.00
+14.5%from $25.33
Nov 24, 2025Guggenheim
Pfizer price target raised to $35 from $33 at Guggenheim
Target:$35.00
+39.1%from $25.17
Nov 5, 2025Goldman Sachs
Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'
Target:$26.00
+7.3%from $24.23
Oct 31, 2025Bernstein
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera
Target:$30.00
+22.7%from $24.45
Oct 10, 2025Morgan Stanley
Pfizer price target lowered to $32 from $33 at Morgan Stanley
Target:$32.00
+26.8%from $25.24
Oct 1, 2025UBS
Pfizer drug pricing deal 'mostly performative,' says BofA
Target:$28.00
+3.1%from $27.16
Apr 22, 2025Cantor Fitzgerald
Pfizer initiated with a Neutral at Cantor Fitzgerald
Target:$24.00
+6.5%from $22.53
Dec 18, 2024Truist Financial
Pfizer price target lowered to $32 from $36 at Truist
Target:$32.00
+23.6%from $25.89
Oct 30, 2024Goldman Sachs
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
Target:$33.00
+16.0%from $28.46
Oct 17, 2024Bernstein
Pfizer initiated with a Market Perform at Bernstein
Target:$32.00
+7.9%from $29.67
Sep 25, 2024Barclays
Pfizer withdrawal raises business development questions, says Barclays
Target:$32.00
+10.6%from $28.93
Aug 7, 2024Daiwa
Daiwa Securities Upgrades Pfizer (PFE) to Outperform (2)
Target:$34.00
+17.9%from $28.85
Jul 31, 2024Wells Fargo
Pfizer price target raised to $30 from $28 at Wells Fargo
Target:$30.00
-4.4%from $31.39
Jul 31, 2024Goldman Sachs
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
Target:$34.00
+8.3%from $31.39
Jul 30, 2024Guggenheim
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Target:$36.00
+17.2%from $30.72
Jul 10, 2024Barclays
Pfizer price target raised to $30 from $28 at Barclays
Target:$30.00
+8.2%from $27.72
May 22, 2024BMO Capital
Pfizer cost reduction program a positive for the shares, says BMO
Target:$36.00
+21.6%from $29.60
Feb 14, 2024Cantor Fitzgerald
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Target:$45.00
+66.9%from $26.97

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance